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a b s t r a c t   
In response to the coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), global efforts are focused on the development of new therapeutic in-
terventions. For the treatment of COVID-19, selective lung-localizing strategies hold tremendous potential, 
as SARS-CoV-2 invades the lung via ACE2 receptors and causes severe pneumonia. Similarly, recent reports 
have shown the association of COVID-19 with decreased 25-hydroxycholesterol (25-HC) and increased 
cytokine levels. This mechanism, which involves the activation of inflammatory NF-κB- and SREBP2- 
mediated inflammasome signaling pathways, is believed to play a crucial role in COVID-19 pathogenesis, 
inducing acute respiratory distress syndrome (ARDS) and sepsis. To resolve those clinical conditions ob-
served in severe SARS-CoV-2 patients, we report 25-HC and didodecyldimethylammonium bromide (DDAB) 
nanovesicles (25-HC@DDAB) as a COVID-19 drug candidate for the restoration of intracellular cholesterol 
level and suppression of cytokine storm. Our data demonstrate that 25-HC@DDAB can selectively accu-
mulate the lung tissues and effectively downregulate NF-κB and SREBP2 signaling pathways in COVID-19 
patient-derived PBMCs, reducing inflammatory cytokine levels. Altogether, our findings suggest that 25- 
HC@DDAB is a promising candidate for the treatment of symptoms associated with severe COVID-19 pa-
tients, such as decreased cholesterol level and cytokine storm. 
© 2021 The Author(s). Published by Elsevier Ltd. 
CC_BY_NC_ND_4.0   
Introduction 
Scientists of various disciplines have joined the race to develop 
therapeutics against the coronavirus disease (COVID-19) pandemic 
since the outbreak at the end of 2019 [1]. Although most research 
has focused on eliminating the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) itself, it is of vital importance to un-
derstand the indispensable role of anti-inflammatory interventions 
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in the treatment of COVID-19 [2]. The patients with reduced im-
munity are vulnerable to SARS-CoV-2 and more prone to develop 
severe complications, such as cytokine release syndrome (CRS), re-
sulting in excessive and uncontrollable inflammatory responses  
[3,4]. Recently, it has been suggested that the reduction in blood type 
I IFNs is one of the hallmarks of severe COVID-19 and thus can be 
used to screen high-risk patients [5]. The study revealed that im-
pairment of type I IFN activity and its reduced production by SARS- 
CoV-2 infection trigger exacerbation of inflammation, chemotaxis of 
monocytes, multiple organ failure, and death [5]. 
Notably, type I IFN level is closely associated with the regulation 
of cholesterol 25-hydroxylase (CH25H) expression [6]. CH25H is an 
enzyme that catalyzes the hydroxylation of cholesterol at carbon 
position 25 to generate 25-hydroxycholesterol (25-HC) [7]. It is 
considered that cytokines like type I interferons (IFNs) can provide 
suppressive effects against the inflammatory responses induced by 
viral infections. Previously, it was reported that upon infection, the 
expression of CH25H is increased via induction of type I IFNs 
through the IFN receptor and the JAK/STAT1 pathway [6]. In addition, 
it has been reported that 25-HC is a critical inhibitor of sterol reg-
ulatory element-binding protein 2 (SREBP2)-mediated cytokine 
production and apoptosis [8,9]. Ch25h-deficient mice demonstrated 
vulnerability to septic shock, displaying increased neutrophil counts 
and inflammasome activity via SREBP2 activation [9]. Since 1950s, it 
has been well established that viral infection induces lowered cho-
lesterol levels [10–18]. In addition, 25-HC possesses broad-spectrum 
anti-viral activities against coronaviruses, including porcine epi-
demic diarrhea virus (PEDV) and transmissible gastroenteritis virus 
(TGEV) [19]. As evidenced by the cases of chloroquine, remdesivir, 
and lopinavir/ritonavir [20,21], drug repositioning offers a highly 
efficient and low-cost way to develop therapeutic agents [2]. Given 
the anti-inflammatory and anti-viral activities, 25-HC was adopted 
as a drug candidate for the treatment of COVID-19 in our in-
vestigation. 
More specifically, we hypothesized that the lung-selective de-
livery of 25-HC could inhibit SARS-CoV-2 replication and suppress 
excessive inflammatory responses, thereby improving the mortality 
rate of severe COVID-19 patients. To achieve a high lung deposition 
of 25-HC, we employed selective organ localization technique  
[22,23], where 25-HC and didodecyldimethylammonium bromide 
(DDAB) were fabricated into nanovesicles, namely 25-HC@DDAB. 
DDAB is a cationic lipid that can serve as not only a 25-HC stabilizing 
agent by forming liposome-like structures but also a lung-homing 
moiety by inducing transient erythrocyte agglutination [24–26]. 
Considering the current situation where no effective therapeutics 
that can inhibit both viral infection and disease progression towards 
ARDS or sepsis, our novel nanotherapeutics could hold promise in 
the fight against COVID-19. 
Experimental section 
Reagents 
Dimethyldioctadecylammonium bromide (DDAB) and 25-hydro-
xycholesterol (25-HC) were purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). Amine-functionalized Cy5.5 was purchased from 
BioActs (Incheon, Korea). 
Plasma sample 
Whole blood was collected from patients admitted at Yeungnam 
University Medical Center after they were diagnosed with the SARS- 
CoV-2 infection at the Public Health Center in Daegu, Republic of 
Korea. Patients with COVID-19 sepsis were defined using criteria 
provided by the Sepsis Consensus Conference Committee [27]. 
Pneumonia and septic shock patients were collected from patients 
admitted at Yeungnam University Medical Center. Healthy volun-
teers were used as controls. Clinical data were collected for all the 
patients. Plasma samples were prepared by centrifugation at 2000g 
for 5 min within 12 h after whole blood collection. The human study 
protocol was approved by the Institutional Review Board of 
Yeungnam University Hospital at Daegu in Korea (YUH 2020-03-057, 
2020-05-031-001). Whole blood was collected from patients after 
approval for use in the study. Blood sample analysis received at the 
hospital was conducted in blind. After analysis, it was compared 
with patient information and then analyzed. MD June Hong Ahn 
collected patient information and provided blood samples in blinded 
manner. After receiving the blind samples, Wonhwa Lee, Hong Nam 
Kim, and Hee Ho Park were in charge of blood analysis and PBMC 
experiments. Afterwards, all the information was collected and or-
ganized, and the patient's personal information were re-analyzed 
very strictly and accurately by Jinmyoung Joo and Dong Hee Na. 
Viruses in the blood were observed in COVID-19 patients, and pro-
gression toward severe respiratory disease or sepsis was progressed 
based on the Cohort study of patients. Patients with COVID-19 sepsis 
were defined using criteria provided by the Sepsis Consensus Con-
ference Committee [27]. Eligible patients met the following criteria: 
age, over 18 years; and an acute onset medical condition with as at 
least one of the following criteria: fever (tympanic temperature 
≥ 38 °C at the nurse triage), suspected systemic infection, two or 
more systemic inflammatory response syndrome SIRS criteria, hy-
potension (systolic blood pressure < 90 mmHg), and/or shock. 
Healthy volunteers were used as controls. Clinical data were col-
lected for all the patients. COVID-19 patients were categorized de-
pending on the disease severity. “Mild” is defined as patients 
receiving quarantine treatment in general ward or those with 
asymptomatic symptoms. “Severe” is defined as patients with ARDS, 
sepsis, or receiving intensive care in the ICU. It also includes patients 
treated with oxygen therapy or those that rely on mechanical 
breathing machines (i.e. ventilators). Similar to previous findings, it 
was noticeable that most severe patients were elderlies with age 
over 70 [28]. 
Quantification of cholesterols in patients blood 
The Human 25-Hydroxycholesterol (25-HC) ELISA Kit 
(MyBioSource, MBS9364825), total cholesterol, HDL-Cholesterol, 
and LDL-Cholesterol dataset were analyzed using the modular DPE 
system (Roche Diagnostics, Basel, Switzerland). 
Preparation and characterization of lung-localizing 25-HC@DDAB 
DDAB and 25-HC were dissolved in methanol and ethanol, re-
spectively. Each solution was blended to be the DDAB/25-HC weight 
ratio of 2, 4, or 6. The solvent was evaporated for 3 h at 70 °C using a 
heating block (Eyela MG-2200, Tokyo, Japan). The resulting compo-
site films were resuspended with double-deionized water (DDW) to 
be the final 25-HC concentration of 1 mg/mL using ultrasonication 
(VC-750; Sonics & Materials, Inc., Newtown, CT, USA) at an ampli-
tude of 20% with a pulse cycle of 2 s on and 3 s off. Cy5.5-loaded 
25-HC@DDAB was prepared using the same method above, except 
that 70 μg of Cy5.5 was added before the solvent evaporation pro-
cedure. The particle size, polydispersity index, and zeta potential of 
the resulting nanohybrids (NHs) were measured by Zetasizer Ultra 
(Malvern Panalytical, Malvern, UK) according to the manufacturer's 
protocol. The morphology of 25-HC@DDAB was observed using 
transmission electron microscopy (Talos L120C; FEI, Hillsboro, OR, 
USA) at a cryogenic temperature. The samples (5 μL) were placed 
onto the surface of carbon-coated copper grids by the plunge-dip-
ping method and vitrified using liquid ethane cooled by liquid ni-
trogen. The samples were placed onto the surface of carbon-coated 
copper grids and negatively stained with uranyl acetate. To measure 
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the drug encapsulation efficiency (EE), the 25-HC concentration of 
the prepared NH suspension was determined by using a high-per-
formance liquid chromatography (HPLC) system (Agilent 1260 in-
finity; Agilent Technologies, Palo Alto, CA, USA) equipped with a 
Kinetex C18 column (4.6 mm × 250 mm, 5 µm; Phenomenex, 
Torrance, CA, USA). The chromatographic separation was performed 
in an isocratic elution mode (flow rate: 1.8 mL/min), where the 
mobile phase consisted of acetonitrile and DDW (80:20, v/v). The 
detection wavelength for 25-HC was 205 nm. The analytical samples 
were prepared by disrupting the 25-HC@DDAB with ethanol (40 × 
volume). The injection volume and lower limit of quantitation 
(LLOQ) were 20 μL and 1 µg/mL, respectively. The retention time of 
25-HC and total run time were 7.8 and 10.0 min, respectively. 
Animals and husbandry 
Male C57BL/6 mice (6–7-weeks-old, weighing 18–20 g) were 
purchased from Orient Bio Co. (Sungnam, Korea). Male ICR mice 
(4-weeks-old, weighing 21–24 g) and female BALB/c nude mice 
(5-weeks-old, weighing 18–22 g) were purchased from Nara Biotech 
Co. (Seoul, Korea). The animals were housed 5 per polycarbonate 
cage under controlled temperature (20–25 °C) and humidity 
(40–45%) under a 12:12 h light/dark cycle, fed a normal rodent pellet 
diet, and supplied with water ad libitum. All animals were used after 
a 12-day acclimatization period and treated in accordance with the 
Guidelines for the Care and Use of Laboratory Animals issued by 
Chungnam National University (IRB No.; CNU-01050). 
Cecal ligation and puncture (CLP) 
For induction of sepsis, male mice were anesthetized with 2% 
isoflurane (Forane, JW pharmaceutical, South Korea) in oxygen de-
livered via a small rodent gas anesthesia machine (RC2, Vetequip, 
Pleasanton, CA), first in a breathing chamber and then via a face-
mask. They were allowed to breath spontaneously during the pro-
cedure. The CLP-induced sepsis model was prepared as previously 
described [29]. In brief, a 2 cm midline incision was made to expose 
the cecum and adjoining intestine. The cecum was then tightly li-
gated with a 3.0-silk suture at 5.0 mm from the cecal tip and 
punctured once using a 22-gauge needle for induction of high grade 
sepsis [29]. It was then gently squeezed to extrude a small amount of 
feces from the perforation site and returned to the peritoneal cavity. 
The laparotomy site was then sutured with 4.0-silk. In sham control 
animals, the cecum was exposed but not ligated or punctured and 
then returned to the abdominal cavity. 
In vivo biodistribution of 25-HC@DDAB 
Male ICR mice were injected with free Cy5.5 or Cy5.5-loaded 
25-HC@DDAB via tail vein at a Cy5.5 dose of 35 μg/kg. Free Cy5.5 
injection solution was prepared by diluting an aliquot (7 μL) of Cy5.5 
stock solution (1 mg/mL, dissolved in DMSO) with normal saline 
(993 μL) by vortex-mixing. At each time point (3, 6, 9, 12, 24, and 
48 h post-injection), three biologically independent animals were 
sacrificed and their organs (liver, kidney, spleen, heart, and lung) 
were dissected for ex vivo imaging. The biodistribution of free Cy5.5 
or Cy5.5-loaded 25-HC@DDAB was monitored by measuring fluor-
esce intensity of each organ using VISQUE® InVivo Smart (Vieworks, 
Anyang, Korea). As control carriers, egg phosphatidylcholine (EPC; 
Lipoid E100; Lipoid AG, Ludwigshafen, Germany)-blended NHs, in-
cluding Cy5.5-loaded 25-HC@EPC and Cy5.5-loaded 25-HC@DDAB/ 
EPC, were fabricated using the aforementioned method (see 
Preparation and characterization of lung-localizing 25-HC@DDAB), 
except that the feed ratios of DDAB/EPC/25-HC were set at 0/4/1 and 
2/2/1, respectively. These control carriers were also evaluated using 
the same experimental design above. At 6 h post-injection, the 
animals were euthanized, and their major organs were eviscerated 
for imaging. The radiant efficiency value of each organ was com-
pared with that of 25-HC@DDAB. Cy5.5-loaded 25-HC@DDAB was 
also administered to the male ICR mice intravenously 12 h after CLP 
operation at the same Cy5.5 dose. The mice were euthanized at 3, 6, 
and 12 h post-injection, and the ex vivo imaging was performed on 
the major organs according to the same protocol above. For in vivo 
imaging, CLP-operated BALB/c nude mice were administered with 
Cy5.5-loaded 25-HC@DDAB at a Cy5.5 dose of 35 μg/kg, and the 
whole-body scan was carried out at 30, 60, 90, 120, 180, 240, and 
360 min post-injection. The radiant efficiency of the thorax region 
was measured using CleVue™ software (Vieworks). 
PBMC isolation and culture 
Samples from healthy, SARS-CoV-2 pneumonia patients, or dis-
charged patients were obtained from Yeungnam University Medical 
Center. The relevant local Institutional Review Boards and Ethics 
Committees approved the study. Heparinized blood samples were 
used fresh within 4 h, and peripheral blood mononuclear cells 
(PBMCs) were separated from blood using Ficoll–Hypaquek or 
NycoPrepk according to the manufacturer’s recommendations. 
Following this, more refined PBMCs were obtained via MACSprep™ 
PBMC Isolation Kit and cultured in RPMI-1640 with 1 mM Sodium 
pyruvate, 2 mM L-glutamine, 4.5 mg/L glucose, 10 mM HEPES and 
2 mg/L sodium bicarbonate. 
Western blotting 
Ch25h were detected by immunoblotting, in separated PBMCs 
from mild COVID-19 or severe COVID-19. After sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, we performed an immunoblotting 
assay with monoclonal mouse anti-Ch25h antibodies (CH25H 
monoclonal antibody (M01), clone 1G8, H00009023-M01, Abnova). 
Inflammatory cytokines IL-1β, and TNF-α ELISAs 
Serum levels of inflammatory cytokines IL-1β, and TNF-α were 
determined in SARS-CoV-2-infected patients using human ELISA kits 
(Quantikine ELISA, R&D Systems, Minneapolis, MN, USA) according 
to the manufacturer’s instructions. PBMCs isolated from patient 
blood were treated with 0.5 or 1.0 μM 25-HC or 25-HC@DDAB for 
12 h. The results were expressed as pg/mL. 
WST-1 cell proliferation assay 
10 μL per well of WST-1 reagent were added in purified PBMC, 
HUVECs, or MRC-5 (human fetal lung fibroblast cell line) and in-
cubated at 37 °C with 5% CO2. At indicated time points, measure-
ments of absorbance were taken at 480 nm and 600 nm 
(background) on Tecan Spark microplate reader. 
Cytokines profiling 
PBMCs isolated from patient blood were treated with 0.5 or 
1.0 μM 25-HC or 25-HC@DDAB for 12 h. Plasma pools of patients 
with normal or severe COVID-19 patients were processed as in-
dicated in the Human XL Cytokine Array Kit (R&D Systems). 
Developed films were scanned, the obtained images were analyzed 
using ImageJ version 1.43. 
Real-time PCR 
PBMCs isolated from patient blood were treated with 0.5 or 
1.0 μM 25-HC or 25-HC@DDAB for 12 h. To generate cDNA from 
PBMCs, SN50/Fatostatin A treated PBMCs, or SN50/Fatostatin A 
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administrated septic mouse lung tissue samples, 1 μg of total RNA 
was reverse transcribed with random hexamers using expand re-
verse transcription polymerase (Roche). Real-time PCR was per-
formed using the LightCycler FastStart DNA Master SYBR Green I 
from Roche Diagnostics GmbH according to the manufacturer’s 
protocol. The following LightCycler conditions were used: Initial 
denaturation at 95 °C for 10 min, followed by 45 cycles with dena-
turation at 95 °C for 10 min, annealing at 60 °C for 5 min, and 
elongation at 72 °C for 15 min. Quantities of specific mRNA in the 
sample were measured according to the corresponding gene-specific 
standard curves.    
Gene 
symbol 
Forward primer Reverse primer  
SREBF2 CCTTCCTGTGCCTCTCCTTTA AGGCATCATCCAGTCAAACCA 
IL1B TACCTGTCCTGCGTGTTGAAA CTGCTTGAGAGGTGCTGATGT 
TNF TGGCGTGGAGCTGAGAGATAA TTGATGGCAGAGAGGAGGTTGA 
NLRP3 TGCCGGGGCCTCTTTTCAGT CCACAGCGCCCCAACCACAA 
NOX AACGAATTGTACGTGGGCAGA GAGGGTTTCCAGCAAACTGAG 
MCP-1 CGCTCAGCCAGATGCAATCAATGC GGTTTGCTTGTCCAGGTGGTCCA 
Srebf2 TGTGGCTGGTAAATGGTGTGA AGCACGGATAAGCAGGTTTGT 
Nox2 ACTCCTTGGAGCACTGG GTTCCTGTCCAGTTGTCTTCG 
Nlrp3 TCGCCCAAGGAGGAAGAAGAA TGAGAAGAGACCACGGCAGAA 
Il-1β GGTGTGTGACGTTCCCATTAG TCGTTGCTTGGTTCTCCTTGT 
Icam-1 GCTACCATCACCGTGTATTCG TAGCCAGCACCGTGAATGTG 
Mcp-1 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
β-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT  
Isolation of endothelial cell from mouse 
The endothelial cells were isolated according to the manufac-
turer's (Dynal Biotec, Lake Success, NY) instructions, using 
Dynabeads coupled to anti-CD31 antibody and the Dynal Magnetic 
holder. Briefly, for endothelial cell isolation, four to six mice (6–10 
weeks old) were anesthetized, followed by exposure of the perito-
neal cavity. Excised lungs and hearts put into RPMI media and re-
move other tissues from heart and lungs, and then rinse once in PBS. 
The lung and hearts incubate with 1.0 mg/mL of collagenase A in a 
50 mL tube for 1 h, rocking at 37 °C. Every 5 min during this in-
cubation, the tube was gently agitated for a few seconds, and then 
transfer the suspension into a new 50 mL tube by passing it through 
the 70 µm tissue sieve (BD Falcon). The filtered cell suspension was 
centrifuged for 10 min at 1000 rpm. After removal of the super-
natant, the cell pellet was washed once with cold PBS in a new 
15-mL tube. To prepare the Dynabead-coupled anti-mouse CD31 
antibody, Dynabeads (60 μL) were washed with MACS buffer (PBS, 
0.5% BSA, 2 mM EDTA) on a magnetic holder (Invitrogen). The 
Dynabeads were resuspended with MACS buffer (600 μL), anti- 
mouse CD31 (5 μg of per 10 μL of beads) was added, and the mixture 
was incubated for 12 h at 4 °C. Cells were incubated with Dynabead- 
coupled anti-mouse CD31 antibody for 10 min at room temperature 
and then placed in a magnetic holder. Cell suspension was slowly 
added to a 15 mL tube by placing the pipette on the wall of the tube. 
After incubation for 5 min, PBS was carefully removed by aspiration. 
The Dynabead-coupled anti-mouse CD31 antibodies were washed 
three times in cold PBS, the pellet was resuspended in EBM-2 growth 
medium, and then harvested and lysed in RIPA buffer containing 
protease inhibitor cocktail (Roche) on ice. 
Cholesterol staining by filipin 
Mouse lung endothelial cells were seeded in a Nunc Lab-Tek II 
8-Chamber Slide and treated with compounds for indicated time 
points. Cells were fixed with 4% paraformaldehyde for 1 h at room 
temperature and then permeabilized with 0.5% Triton X-100 (for 
protein immunostaining) for 10 min prior to blocking in a blocking 
buffer (3% bovine serum albumin (BSA) in PBS containing 0.1% 
Tween-20) for 12 h. Cells were incubated with Filipin staining dye in 
the blocking buffer overnight at 4 °C. Cells were washed with PBS, 
mounted with Immu-mount, and were visualized by fluorescence 
microscopy at a 200× magnification (Leica microsystem, Germany). 
The 25-HC@DDAB was treated at a concentration of 0.1, 1, and 10 μM 
for 24 h. 
Quantification of 25-HC concentration in lung microsomes of 
septic mice 
ICR mice (6-week-old) were administered with 1.0 μM 25-HC@DDAB 
intravenously 12 h after the CLP operation. At 6 h post-injection, the 
mice were euthanized and the lung was dissected. The lung tissue 
homogenate (10%, w/v) was prepared using T25 Ultra-Turrax® (IKA- 
Werke GmbH & Co. KG, Staufen, Germany), wherein the lung was 
homogenized with PBS at 15,000 rpm for 1 min on ice. To isolate mi-
crosomes, the lung homogenate was first centrifuged at 20,000g for 
15 min at 4 °C using Beckman XL‐80 ultracentrifuge (Beckman 
Instruments, Inc., Fullerton, CA, USA). Subsequently, the supernatant was 
collected and centrifuged at 100,000g for 60 min at 4 °C. The pellet 
(microsomes) was collected and resuspended using the test buffer of 
25-HC ELISA kit (MyBioSource, MBS7254215). The quantification of 
25-HC concentration in the microsomal suspension was carried out ac-
cording to the manufacturer’s protocol. 
Cytotoxicity test 
Mouse lung endothelial cells were treated with various con-
centrations of 25-HC@DDAB for 24 h and stained using LIVE/DEAD™ 
Fixable Far Red Dead Cell Stain Kit (L34973, Invitrogen™). Cells were 
then washed twice with PBS. Stained cells were resuspended in 1 mL 
of PBS, and the fluorescence was quantified using a FACScan flow 
cytometer (BD). 
Hematoxylin and eosin staining 
Male C57BL/6 mice underwent CLP and were administered 
25-HC, and 25-HC@DDAB (1 μM) intravenously at 6 h after CLP 
(n = 5). Mice were euthanized 96 h after CLP. To analyze the phe-
notypic change of lung in mice, lung samples were removed from 
each mouse, washed three times in PBS (pH 7.4) to remove re-
maining blood, fixed in 4% formaldehyde solution (Junsei, Tokyo, 
Japan) in PBS, pH 7.4 for 20 h at 4 °C. After fixation, the samples were 
dehydrated through ethanol series, embedded in paraffin, sectioned 
into 4-μm sections, and placed on a slide. The slides were depar-
affinized in a 60 °C oven, rehydrated, and stained with hematoxylin 
(Sigma). To remove over-staining, the slides were quick dipped three 
times in 0.3% acid alcohol, and counterstained with eosin (Sigma). 
They are then washed in ethanol series and xylene, and then cover 
slipped. Light microscopic analysis of lung specimens was performed 
by blinded observation to evaluate pulmonary architecture, tissue 
edema, and infiltration of the inflammatory cells. 
Clinical chemistry and cytokine level in septic mice plasma 
Fresh serum was used for assaying aspartate transaminase (AST), 
alanine transaminase (ALT), blood urea nitrogen (BUN), creatinine, 
and LDH using biochemical kits (Mybiosource). To determine the 
concentrations of IL-1β, IL-6, IL-10, monocyte chemoattractant pro-
tein-1 (MCP-1), and TNF-α commercially available ELISA kits were 
used according to the manufacturer’s protocol (R&D Systems). 
Values were measured using an ELISA plate reader (Tecan, Austria 
GmbH, Austria). 
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In vivo permeability and leukocyte/neutrophil migration assays 
CLP-operated mice were injected with 25HC or 25-HC@DDAB 
intravenously. After 6 h, 1% Evans blue dye solution in normal saline 
was injected intravenously into each mouse. Thirty minutes later, 
the mice were killed, and the peritoneal exudates were collected 
after being washed with normal saline (5 mL) and centrifuged at 
200 × g for 10 min. The absorbance of the supernatant was read at 
650 nm. The vascular permeability was expressed in terms of dye 
(μg/mouse), which leaked into the peritoneal cavity according to a 
standard curve of Evans blue dye. 
For assessment of leukocyte/neutrophil migration, CLP operated 
mice were treated with 25-HC@DDAB (1 μM) after CLP surgery 6 h. 
The mice were then sacrificed and the bronchoalveolar lavage (BAL) 
were washed with 0.8 mL of normal saline [30]. BAL fluid (200 μL) 
was counted by auto hematology analyzer (Mindray, BC 5000 Vet). 
The results were expressed as leukocyte/neutrophil × 105 per 
BAL fluid. 
Expression of ICAMs 
The expression of intercellular adhesion molecule-1 (ICAM-1) on 
lung tissues was determined by a direct ELISA. The lysed lung tissues 
were coated onto Nunc-Immuno™ MicroWell™ 96 well plates and 
incubated overnight at 4 °C. After washing, anti-mouse monoclonal 
ICAM-1 antibodies (Millipore Corporation, Billerica, MA, 1:50 each) 
were added. After 1 h (37 °C, 5% CO2), the cells were washed three 
times and then 1:2000 peroxidase-conjugated anti-mouse IgG an-
tibody (100 μL; Sigma, Saint Louis, MO) was added for 1 h. The cells 
were washed again three times and developed using the o-pheny-
lenediamine substrate (Sigma, Saint Louis, MO). Colorimetric ana-
lysis was performed by measuring absorbance at 490 nm. All 
measurements were performed in triplicate wells. 
Cytokine levels in the plasma of septic mice 
Fresh serum was used for analysis of AST, ALT, BUN, creatinine, 
and LDH levels using biochemical kits (MyBioSource). Values were 
measured using an ELISA plate reader (Tecan, Austria GmbH, 
Austria). 
SREBP-2 transcriptional activity assays 
The transcriptional activities of SREBP-2 were determined by the 
ELISA method using kits from Abcam (ab133111, Abcam) following 
manufacturer’s protocol. Briefly, nuclear homogenate equivalent to 
30 μg of the protein content was added to each of the wells of the 
96-well plate containing the double-stranded DNA sequence har-
boring the consensus SREBP-binding sequence (sterol regulatory 
element, SRE) coated onto the wells. The nuclear extract was allowed 
to hybridize with the coated double-stranded DNA sequence har-
boring the consensus SRE (sterol regulatory element) in the plate 
overnight at 4 °C. The activated SREBP transcription factor complex 
was detected by addition of a specific primary antibody directed 
against SREBP-2 and a secondary antibody conjugated to HRP added 
to provide a sensitive colorimetric readout at 450 nm. 
NF-κB transcriptional activity assays 
Preparation of nuclear extracts and TransAM assays were per-
formed as previously described [31]. The activity of individual NF-κB 
subunits was determined using an ELISA-based NF-κB Family Tran-
scription Factor Assay Kit (43296; Active Motif, Carlsbad, CA, USA). 
Briefly, nuclear extracts (2 µg) were incubated in a 96-well plate, 
which was coated with NF-κB consensus oligonucleotides. The cap-
tured complexes were incubated with specific NF-κB primary Abs and 
subsequently detected using HRP-conjugated secondary Abs included 
with the kit. Finally, the optical density (OD) at 450 nm was measured 
using a Tecan Spark microplate reader (Tecan, Austria GmbH, Austria). 
Statistical analysis 
All the in vitro and in vivo data were analyzed via two-tailed 
unpaired t-test using the Graphpad prism 7 software, the prepared 
sample sizes were n ≥ 3, and the statistical significance was set at 
P  <  0.05. A more detailed information for each experiment is pro-
vided in the figure legend. All data normalization processes were 
carried out according to the manufacturer’s protocol. Data trans-
formation and evaluation of outliers were not used in our study. 
Results 
Decreased 25-HC, LDL, HDL, and total cholesterol in severe COVID-19 
patients 
According to the analysis of COVID-19 patients’ plasma, we found 
that the levels of blood cholesterol, including 25-HC, low-density li-
poprotein (LDL) cholesterol, high-density lipoprotein (HDL) choles-
terol, and total cholesterol, were significantly reduced in severe cases 
of COVID-19 patients compared to mild cases (Fig. S1a). Similar to 
previous findings, it was noticeable that most severe patients were 
elderlies with age over 70 [28]. Among them, the level of 25-HC de-
creased more than six-fold from 17.5  ±  10.5 μg/mL to 2.8  ±  4.9 μg/mL. 
Noteworthy is that patients with a low 25-HC level exhibited more 
severe signs of lung inflammation, as can be seen in the chest com-
puted tomography (CT) images (Fig. S1b). 
Preparation and characterization of 25-HC@DDAB 
However, due to the poor water solubility (≈224 ng/mL), the in-
travenous administration of 25-HC should be preceded by an ap-
propriate solubilization procedure. Inspired by a conventional 
liposome structure composed of vesicle-forming amphiphilic lipids 
and membrane-stabilizing cholesterols, we successfully prepared 
25-HC@DDAB via the film-hydration method, which displayed ve-
sicle-like morphology (Fig. 1a and b). Dynamic light scattering ana-
lysis revealed that nanohybrids (NHs) with DDAB/25-HC weight 
ratio of 4 showed an optimal average diameter of 126.5  ±  2.3 nm 
(polydispersity index [PDI] of 0.26  ±  0.01) and positively-charged 
zeta potential of 93.26  ±  3.84 mV. The NHs with DDAB/25-HC 
weight ratio of 2 or 6 were excluded from further investigations due 
to the larger particle size (179.3  ±  8.6 nm) or broader size dis-
tribution (PDI of 0.72  ±  0.10), respectively, compared to those with 
the weight ratio of 4. The encapsulation efficiency of 25-HC was 
determined to be 101.7  ±  1.3% by using high-performance liquid 
chromatography analysis. Cy5.5 was loaded to the nanohybrids as a 
fluorescent probe, of which mean diameter was 204.2  ±  4.1 nm 
(Fig. 1c and d). It is worth noting that the intravenously administered 
NHs exhibited preferential accumulation to the lung with high effi-
ciency compared to the other organs (Fig. 1e and f). Even 48 h after 
the administration, the average radiant efficiency of the lung in the 
NH-treated group was 2.6-fold higher than that in the free Cy5.5- 
treated group (p  <  0.05) (Fig. 1g). This lung localization of NHs can 
be explained by the transient aggregation with red blood cells (RBCs) 
via electrostatic interactions [22,23]. More specifically, the NHs ad-
ministered via peripheral vein first encounter RBCs. Due to the 
electrostatic attractions between NHs (positively-charged) and RBCs 
(negatively-charged), transient aggregates can be generated in the 
blood stream, which are then perfused into the pulmonary circula-
tion. The transient aggregates with large particle size can be retained 
in the pulmonary capillary, increasing the chances of lung retention 
of NHs. Notably, negatively-charged or less positively-charged 
H. Kim, H.S. Lee, J.H. Ahn et al. Nano Today 38 (2021) 101149 
5 
control NHs displayed a significantly compromised lung distribution 
compared to 25-HC@DDAB, which indicates that the enhanced lung 
disposition of the developed NHs can be attributed to their posi-
tively-charged zeta potential (Fig. S2). The mouse lung tissue lysate 
also showed a higher level of 25-HC upon the delivery of 25-HC@ 
DDAB than 25-HC alone, supporting the enhanced lung delivery ef-
ficiency of the developed NHs (Fig. S2). The improved lung dis-
tribution suggests that 25-HC@DDAB can be an efficient tool for 
treating respiratory diseases. Although most 25-HC@DDAB was lo-
calized in the lung tissue after intravenous injection, the agents 
could still remain in blood circulation, causing undesirable vascular 
toxicity. Thus, we evaluated cytotoxic effect of the 25-HC DDAB in 
the in vitro-cultured mouse lung endothelial cells (Fig. S3a). The 
mouse lung endothelial cells showed no significant cytotoxic effect 
(Fig. S3b). We also evaluated cytotoxic effect of the 25-HC DDAB in 
the in vitro-cultured human lung endothelial cell (HUVEC) and 
human fetal lung fibroblast cell line (MRC5). The human lung cells 
showed no significant cytotoxic effect (Fig. S4). Moreover, in-
travenous administration 25-HC@DDAB demonstrated no hemato-
toxicity and organ damage (Fig. S5). The filipin staining, which was 
used for the visualization of intracellular cholesterol level, confirmed 
the high level of intracellular cholesterol in isolated mouse lung 
endothelial cells from the 25-HC@DDAB-administered mouse (Fig. 
S3). This result can be attributed in part to the positively-charged 
surface of NHs that allows enhanced cellular uptake via interaction 
with the negatively-charged cell surface. 
Fig. 1. Preparation and evaluation of 25-HC@DDAB nanohybrids (NHs) for lung tissue localization. (a) Schematic illustration of 25-Hydroxycholesterol@ 
Didodecyldimethylammonium bromide (25-HC@DDAB) NHs. (b) Transmission electron microscopy (TEM) image of 25-HC@DDAB. The length of scale bar is 100 nm. (c) 
Characterization of 25-HC@DDAB NHs. Intensity averaged hydrodynamic diameters with polydispersity index and zeta potential values are presented. (d) Size distribution 
diagrams of 25-HC@DDAB NHs are displayed. (e) Ex vivo imaging of dissected organs after the intravenous administration of Cy5.5-loaded 25-HC@DDAB. Representative images 
from each group are shown (n = 5). (f) Relative radiant efficiency of each organ, where the sum of radiant efficiency values of liver, spleen, kidney, heart, and lung at 3 h is set as 
100%. (g) Average radiant efficiency in the lung of Cy5.5-loaded NH-treated group was compared with that of free Cy5.5-treated group according to the elapsed time after 
administration. Statistical analysis was performed using a two-tailed unpaired t-test. Data are presented as mean  ±  standard deviation. *P  <  0.05. 
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Treatment of 25-HC@DDAB ameliorates cytokine storm on PBMC of 
severe COVID-19 patients 
The peripheral blood mononuclear cells (PBMCs) were isolated 
from COVID-19 patients’ blood and analyzed with the western blot to 
confirm the level of CH25H. Indeed, the enzyme level was lower in the 
PBMCs derived from severe COVID-19 patients than those from mild 
COVID-19 patients (Fig. 2a). The mRNA expression of CH25H was also 
downregulated in the PBMCs isolated from severe COVID-19 patients 
(Fig. 2b). Interestingly, the treatment of 25-HC@DDAB significantly 
increased the 25-HC level in PBMCs of severe COVID-19 patients in a 
dose-dependent manner (Fig. 2c). As a result of 25-HC@DDAB treat-
ment, the cell viability of PBMCs derived from severe COVID-19 pa-
tients was rescued (Fig. 2d). Notably, it was demonstrated that the 
25-HC@DDAB could inhibit the cytokine storm. As confirmed by en-
zyme-linked immunosorbent assay (ELISA) (Fig. 2e) and cytokine array 
(Fig. 2f), the 25-HC@DDAB inhibited the excessive production of IL-1β, 
a well-known cytokine involved in cytokine storm. Considering that 
the vascular and lung damages are attributed to cytokine storm, the 
25-HC@DDAB showed promising ability as a mediator of the cytokine 
storm. We utilized two analytical techniques to evaluate the efficacy of 
25-HC@DDAB for the suppression of cytokine storm; enzyme-linked 
immunosorbent assay (ELISA) and cytokine array. Although the uptake 
efficiency of 25-HC@DDAB was higher than that of 25-HC, the reduced 
level of IL-1β was similar, presumably due to the sufficient uptake of 
25-HC during the 12 h treatment period. The expression level of IL-6 
was demonstrated in Fig. 2f, in which the treatment of 25-HC@DDAB 
reduced the expression level of IL-6. We believe that, at least in the in 
vitro assay, the 25-HC@DDAB can suppress the cytokine storm in the 
COVID-19 patient-derived PBMCs. Recently, it was reported that NLRP3 
inflammasome is activated via cholesterol master transcription factor, 
SREBP2 [32]. It may be possible that sterol depletion promotes NLPR3 
inflammasome activation in the lungs and leads to intracellular de-
livery of 25-HC. Additionally, the 25-HC@DDAB reduced the activation 
level of SREBP2, which is known to activate inflammation and TNF-α 
overproduction (Figs. S6 and S7). The mRNA levels related to in-
flammation (IL-1β and TNF-α), reactive oxygen species formation 
(NOX2), and activation of NF-κB signaling (NRLP3) that regulates in-
flammation were downregulated in the PBMCs derived from severe 
COVID-19 patients with the benefit of 25-HC@DDAB (Fig. S8). The 
monocyte chemoattractant protein 1 (MCP1), which regulates the 
chemokine related to vascular inflammatory responses, and SREBP2 
were also downregulated (Fig. S8). These results consistently suggest 
that 25-HC@DDAB could ameliorate the cytokine storm and in-
flammasome-mediated apoptosis by inhibiting SREBP2 activation. 
25. -HC@DDAB increase survival rate of septic mouse model 
To demonstrate the capability of 25-HC@DDAB as a therapeutic 
agent for treating respiratory infectious diseases, a cecal ligation and 
puncture (CLP) animal model was utilized. Although the CLP-treated 
mice showed lethal outcomes, the 25-HC rescued the survival rate to 
30% and the 25-HC@DDAB to 50% (Fig. 3a). The histological analysis 
of lungs from sacrificed mice showed reduced damages to the blood 
vessel and lung tissue in the 25-HC@DDAB treated case (Fig. 3b). The 
plasma analysis of sacrificed mice showed a lower level of 25-HC in 
the blood in the case of 25-HC@DDAB, implying the higher uptake by 
tissue cells (Fig. 3c). The indicators related to inflammation were 
rescued in the 25-HC@DDAB treated groups, such as permeability, 
intercellular adhesion molecules 1 (ICAM-1) expression in lung 
tissue, leukocyte and neutrophil migration in bronchoalveolar lavage 
(BAL), and SREBP2 activity in lung tissue (Fig. 3c). The markers for 
sepsis including C-reactive protein (CRP), lactate dehydrogenase 
(LDH), alanine aminotransferase (ALT), aminotransferase (AST), 
Fig. 2. 25-HC@DDAB suppressed cytokine storm in the PBMCs of severe COVID-19 patients. (a) Western blot analysis of Ch25h level in PBMCs of mild and severe COVID-19 
patients (n = 5/each group). (b) qRT-PCR analysis of ch25h mRNA level (n = 10/each group). (c) Level of 25-HC upon the treatment of 25-HC and 25-HC@DDAB with 0.5 μM and 
1.0 μM concentrations (n = 10/each group). (d) Effect of 25-HC and 25-HC@DDAB in the rescue of survival rate of PBMCs derived from severe COVID-19 patients (n = 10/each group). 
(e) Effect of 25-HC and 25-HC@DDAB in the suppression of IL-1β production quantified by ELISA (n = 5/each group). (f) Effect of 25-HC and 25-HC@DDAB in the suppression of 
cytokine storm as confirmed by cytokine array analysis (n = 3/each group). For the assay, 2 × 106/well of cells per group was treated with 1 μM 25-HC and 25-HC@DDAB in RPMI 
medium without FBS for 12 h. Statistical analysis was performed using a two-tailed unpaired t-test. **P  <  0.01. 
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blood urea nitrogen (BUN), and creatinine were also reduced in the 
25-HC@DDAB treated mouse plasma (Fig. 3d). The absolute neu-
trophil count (ANC) was decreased, and absolute leukocyte count 
(ALC) was increased in the 25-HC@DDAB treated group (Fig. S8). 
Moreover, the SREBP2-related mRNA expression, including Nox2, 
Nrlp3, Il1b, Mcp1, Icam1, and Srebp2, was reduced upon the treat-
ment of 25-HC@DDAB in mouse models (Fig. 3e). As expected, the 
serum cytokine levels such as IL-1β, IL-6, IL-8, and TNF-α were de-
creased in the 25-HC@DDAB treated group, confirming the capability 
of 25-HC@DDAB as a cytokine storm inhibitor (Fig. 3f). 
Discussion 
Since the outbreak of COVID-19 infectious disease, a few studies 
have reported reduced levels of serum cholesterol in COVID-19 pa-
tients [33]. The reduced serum cholesterol level is associated with 
poor clinical outcomes, such as the development of myocardial in-
farction. Because the low serum cholesterol level is also related to 
vulnerability to viral infection, treatment strategies via supple-
mentation of exogenous cholesterol, such as 25-HC, have been uti-
lized in coronavirus infections [19]. This previous report encouraged 
us to evaluate the therapeutic benefits of 25-HC in COVID-19 treat-
ment. For efficient delivery of 25-HC to the lung tissue, we adopted 
DDAB, a cationic surfactant that possesses amphiphilic structure. Due 
to the polar head (ammonium) and non-polar tails (didodecyl chains), 
DDAB formed cationic liposome-like structures with 25-HC. Inter-
estingly, the resulting NHs exhibited highly-enhanced lung localiza-
tion (Figs. 1e, f and S2), as well as improved cellular uptake of 25-HC 
in isolated mouse lung endothelial cells (Fig. S3) compared to 25-HC 
alone. The enhanced intracellular transport with the aid of DDAB 
increased the 25-HC concentration in the endoplasmic reticulum 
(Fig. S2h) and promoted the efficacy of 25-HC-mediated cytokine 
suppression and downregulation of inflammation-related signaling. 
Notably, intracellular invasion of SARS-CoV-2 virus by recognizing the 
ACE2 receptors in the lung leads to COVID-19 infection, resulting in 
significant lung tissue damage and inflammation[34,35] Therefore, 
selective lung localizing capability of 25-HC@DDAB could be a sig-
nificant finding towards the development of therapeutics for virus- 
mediated infectious respiratory diseases. 
The major causes of death from bacterial or viral infections are 
mostly ARDS and sepsis [36]. It is well-known that deadly viruses or 
bacteria can cause cytokine storms in the blood, causing severe 
vascular inflammation that leads to multiple organ failure (MOF)  
[37,38]. The mortality rate at the onset of sepsis is very high [39], 
where no sign of improvement even after the clearance of the in-
fectious agents often leads to poor prognosis [40]. Thus, the devel-
opment of drug candidates that can suppress cytokine storms and 
prevent MOF is vital to the establishment of an efficient therapeutic 
regimen for infectious diseases like COVID-19 [41,42]. According to 
the experiment conducted in sepsis animal model, the 25-HC@DDAB 
was proven to be effective in sepsis. Upon the septic condition, the 
administration of 25-HC@DDAB exhibited its efficacy within 48 h 
and increased the survival rate by 50% (Fig. 3a). According to the 
ELISA and RT-PCR analyses, the administered 25-HC@DDAB sup-
pressed inflammation, septic marker expression, and cytokine 
overproduction (Figs. 3c–e and S7–S9). Especially, the 25-HC regu-
lated the SREBP2 signaling, which is known as a critical mediator of 
inflammation and downstream signaling of NF-κB [43,44]. The in-
hibition of SREBP2 could effectively suppress the cytokine storm. 
The correlation of the dysregulated cholesterol level and severity of 
COVID-19 infectious disease is an important issue. 25-HC is produced 
as a result of cholesterol oxidation, and this oxidation is regulated by 
the enzyme cholesterol-25-hydroxylase. Recent studies found that the 
increased level of 25-HC in the severe COVID-19 patients’ sera [45], and 
the exogenous treatment in the SARS-CoV-2-infected cells and hACE2 
mice models decreased the viral load. In terms of the mechanism, the 
25-HC blocks the membrane fusion between the viral and cell mem-
branes, acting as a SARS-CoV-2 inhibitor [45,46]. In regards to biosafety, 
it was shown that administration of 25-HC at 1000 mg/kg did not cause 
any adverse effects in mice models [45]. According to their recent re-
ports, the serum level of 25-HC was increased while other cholesterol 
levels were decreased. These results demonstrate that the administered 
25-HC does not compensate for the reduced 25-HC level, but rather 
regulates the viral load. 
Recently, the World Health Organization (WHO) welcomed the 
dexamethasone being a promising candidate for severe COVID-19 
treatment. Its initial clinical trial demonstrated that regulation of 
inflammation is a key factor for the treatment of COVID-19-mediated 
pneumonia. Our data support that 25-HC@DDAB can also down-
regulate inflammatory pathways. Furthermore, considering that 
cholesterol administration is a widely used strategy for the treat-
ment of critically ill patients, the 25-HC@DDAB can be applied to the 
treatment of various respiratory infectious diseases. 
Conclusion 
In conclusion, we demonstrated inhibition of cytokine storm via 
downregulation of inflammatory NF-κB and SREBP2 signaling path-
ways in COVID-19 patient-derived PBMCs by using 25-HC@DDAB. 
The developed NHs could effectively accumulate lung tissues with 
remarkable accumulation efficiency. Moreover, 25-HC@DDAB in a 
septic mouse model exhibited enhancement of the survival rate. 
Considering the absence of approved therapeutics for SARS-CoV-2 
pneumonia, it is anticipated that 25-HC@DDAB could be a promising 
candidate for modulation of lung tissue damage and cytokine storm 
in severe COVID-19 patients. 
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